Rx orphan drug revenues annual growth worldwide 2011-2024

Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.

This statistic displays the annual growth in worldwide revenues generated by prescribed orphan drugs from 2011 to 2024. During 2018, orphan drugs revenues increased by 11.1 percent. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.

Global prescription orphan drug annual growth in revenues from 2011 to 2024

Characteristic	Growth per year
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

April 2019

More information

Region

Worldwide

Survey time period

as of April 2019

Supplementary notes

Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this analysis. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
* From 2019 on projected.

Citation formats